Skip to main content

Advertisement

Table 2 Inhaler technique, device mastery and device preference in the cross-sectional phase

From: Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study

Device mastery Empty Spiromax (N = 481) Empty Turbuhaler (N = 481) Odds ratio (95% CI)a P-value
Step 1 (Intuitive use), nb (%) [No. of patients participating] 160 (33.3) [481] 55 (11.4) [481] 4.89 (3.23–7.40) < 0.001
Step 2 (Patient information leaflet), nb (%) [No. of patients participating] 386 (80.2) [321] 308 (64.0) [426] 2.95 (2.06–4.22) < 0.001
Step 3 (Instructional video), nb (%) [No. of patients participating] 454 (94.4) [95] 418 (86.9) [173] 3.77 (2.05–6.95) < 0.001
Achievement of dose preparation device mastery (primary endpoint; all patients), n (%) 468 (97.3) 443 (92.1) 4.12 (1.91–8.93) < 0.001
Achievement of inhalation maneuver device mastery (all patients), n (%) 463 (96.3) 445 (92.5) 2.50 (1.28–4.88) 0.007
Number of steps taken to achieve device mastery, median (range) 1 (1–6) 2 (1–5) N/A < 0.001
Number of HCP-observed errors, median (range) 1.91 (0–6) 2.36 (0–6) N/A < 0.001
Patient device preference: PASAPQ score [scale of 1–100], median (range) 89.8c (18.4–100) 85.7c (14.3–100) N/A < 0.001
  1. aOdds ratios are derived from conditional logistic regression of data from paired patients
  2. bNumbers of patients achieving mastery at each stage are cumulative (i.e. patients achieving mastery at previous step(s) are included). Patients demonstrating mastery did not proceed to the next step; they were either proceeded to the second inhaler or finished the study (if they were using the second inhaler)
  3. cn = 477 for each. CI confidence interval, HCP, healthcare professional, N/A not applicable, PASAPQ Patient Satisfaction and Preference Questionnaire